Search

Your search keyword '"Mattavelli, L."' showing total 14 results
Start Over Author "Mattavelli, L." Publication Type Academic Journals
14 results on '"Mattavelli, L."'

1. Repurposing chemotherapy‐induced peripheral neuropathy grading.

Author

Velasco, Roser, Argyriou, Andreas A., Cornblath, David R., Bruna, Pere, Alberti, Paola, Rossi, Emanuela, Merkies, Ingemar S. J., Psimaras, Dimitri, Briani, Chiara, Lalisang, Roy I., Schenone, Angelo, Cavaletti, Guido, Bruna, Jordi, Cavaletti, G., Frigeni, B., Lanzani, F., Mattavelli, L., Piatti, M. L., Alberti, P., and Binda, D.

Subjects
PATIENTS' attitudes, HIERARCHICAL clustering (Cluster analysis), PERIPHERAL neuropathy, DISCRIMINANT analysis, PHYSICIANS
Abstract

Background and Purpose: Chemotherapy‐induced peripheral neuropathy (CIPN) is perceived differently by patients and physicians, complicating its assessment. Current recommendations advocate combining clinical and patient‐reported outcomes measures, but this approach can be challenging in patient care. This multicenter European study aims to bridge the gap between patients' perceptions and neurological impairments by aligning both perspectives to improve treatment decision‐making. Methods: Data were pooled from two prospective studies of subjects (n = 372) with established CIPN. Patient and physician views regarding CIPN were assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI‐CTCAE), Total Neuropathy Scale–clinical version (TNSc) items, and the disease‐specific quality of life ‐ Chemotherapy‐Induced Peripheral Neuropathy questionnaire (QLQ‐CIPN20) from the European Organization for Research and Treatment of Cancer (EORTC). To identify inherent neurotoxic severity patterns, we employed hierarchical cluster analysis optimized with k‐means clustering and internally validated by discriminant functional analysis. Results: Both NCI‐CTCAE and TNSc demonstrated a significant difference in the distribution of severity grades in relation to QLQ‐CIPN20 scores. However, a proportion of subjects with different neurotoxic severity grades exhibited overlapping QLQ‐CIPN20 scores. We identified three distinct clusters classifying subjects as having severely impaired, intermediately impaired, and mildly impaired CIPN based on TNSc and QLQ‐CIPN20 scores. No differences in demographics, cancer type distribution, or class of drug received were observed. Conclusions: Our results confirm the heterogeneity in CIPN perception between patients and physicians and identify three well‐differentiated subgroups of patients delineated by degree of CIPN impairment based on scores derived from TNSc and QLQ‐CIPN20. A more refined assessment of CIPN could potentially be achieved using the calculator tool derived from the cluster equations in this study. This tool, which facilitates individual patient classification, requires prospective validation. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

2. Evaluation of the psychometric properties of the EORTC chemotherapy-induced peripheral neuropathy questionnaire (QLQ-CIPN20)

Author

Kieffer, Jacobien M., Postma, Tjeerd J., van de Poll-Franse, Lonneke, Mols, Floortje, Heimans, Jan J., Cavaletti, Guido, Aaronson, Neil K., Cavaletti, G., Cornblath, D. R., Merkies, I. S. J., Postma, T. J., Valsecchi, M. G., Galimberti, S., Rossi, E., Cavaletti, G., Frigeni, B., Lanzani, F., Mattavelli, L., Piatti, M. L., Alberti, P., Binda, D., Bidoli, P., Cazzaniga, M., Cortinovis, D., Bruna, J., Velasco, R., Argyriou, A. A., Kalofonos, H. P., Psimaras, D., Ricard, D., Pace, A., Galiè, E., Briani, C., Lucchetta, M., Campagnolo, M., Torre, C. Dalla, Faber, C. G., Merkies, I. S. J., Vanhoutte, E. K., Bakkers, M., Brouwer, B., Boogerd, M., Lalisang, R. I., Boogerd, W., Brandsma, D., Koeppen, S., Hense, J., Grant, R., Storey, D., Kerrigan, S., Schenone, A., Reni, L., Piras, B., Fabbri, S., Pessino, A., Padua, L., Granata, G., Leandri, M., Ghignotti, I., Plasmati, R., Pastorelli, F., Postma, T. J., Heimans, J. J., Eurelings, M., Meijer, R. J., Grisold, W., Pozza, E. Lindeck, Mazzeo, A., Toscano, A., Russo, M., Tomasello, C., Altavilla, G., Prado, M. Penas, Gonzalez, C. Dominguez, Dorsey, S. G., and In Collaboration with the CI-PeriNomS Group

Published
2017
Full Text
View/download PDF

3. Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin

Author

Cavaletti, G., Cornblath, D.R., Merkies, I.S.J., Postma, T.J., Valsecchi, M.G, Galimberti, S., Rossi, E., Frigeni, B., Lanzani, F., Mattavelli, L., Piatti, M.L., Alberti, P., Binda, D., Bidoli, P., Cazzaniga, M., Cortinovis, D., Bruna, J., Velasco, R., Argyriou, A.A., Kalofonos, H.P., Psimaras, D., Ricard, D., Pace, A., Galiè, E., Briani, C., Lucchetta, M., Campagnolo, M., Dalla Torre, C., Faber, C.G., Vanhoutte, E.K., Bakkers, M., Brouwer, B., Lalisang, R.I., Boogerd, W., Brandsma, D., Koeppen, S., Hense, J., Grant, R., Storey, D., Kerrigan, S., Schenone, A., Reni, L., Piras, B., Fabbri, S., Padua, L., Granata, G., Leandri, M., Ghignotti, I., Plasmati, R., Pastorelli, F., Heimans, J.J., Eurelings, M., Meijer, R.J., Grisold, W., Lindeck Pozza, E., Mazzeo, A., Toscano, A., Tomasello, C., Altavilla, G., Penas Prado, M., Dominguez Gonzalez, C., Dorsey, S.G., Brell, J.M., and Valsecchi, M.G.

Published
2014
Full Text
View/download PDF

4. Rasch-built Overall Disability Scale for patients with chemotherapy-induced peripheral neuropathy (CIPN-R-ODS)

Author

Galimberti, S., Lanzani, F., Mattavelli, L., Piatti, M.L., Bidoli, P., Cazzaniga, M., Cortinovis, D., Lucchetta, M., Campagnolo, M., Bakkers, M., Brouwer, B., Boogerd, W., Grant, R., Reni, L., Piras, B., Pessino, A., Padua, L., Granata, G., Leandri, M., Ghignotti, I., Plasmati, R., Pastorelli, F., Heimans, J.J., Eurelings, M., Meijer, R.J., Grisold, W., Lindeck Pozza, E., Mazzeo, A., Toscano, A., Russo, M., Tomasello, C., Altavilla, G., Penas Prado, M., Dominguez Gonzalez, C., Dorsey, S.G., Binda, D., Vanhoutte, E.K., Cavaletti, G., Cornblath, D.R., Postma, T.J., Frigeni, B., Alberti, P., Bruna, J., Velasco, R., Argyriou, A.A., Kalofonos, H.P., Psimaras, D., Ricard, D., Pace, A., Galiè, E., Briani, C., Dalla Torre, C., Lalisang, R.I., Brandsma, D., Koeppen, S., Hense, J., Storey, D., Kerrigan, S., Schenone, A., Fabbri, S., Rossi, E., Valsecchi, M.G., Faber, C.G., and Merkies, I.S.J.

Published
2013
Full Text
View/download PDF

5. The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings

Author

Cavaletti, G., Cornblath, D.R., Merkies, I.S.J., Postma, T.J., Rossi, E., Frigeni, B., Alberti, P., Bruna, J., Velasco, R., Argyriou, A.A., Kalofonos, H.P., Psimaras, D., Ricard, D., Pace, A., Galiè, E., Briani, C., Dalla Torre, C., Faber, C.G., Lalisang, R.I., Boogerd, W., Brandsma, D., Koeppen, S., Hense, J., Storey, D., Kerrigan, S., Schenone, A., Fabbri, S., Valsecchi, M.G., Mazzeo, A., Pessino, A., Toscano, A., Brouwer, B., Piras, B., Dominguez Gonzalez, C., Tomasello, C., Binda, D., Cortinovis, D., Lindeck Pozza, E., Vanhoutte, E.K., Lanzani, F., Pastorelli, F., Altavilla, G., Granata, G., Ghignotti, I., Heimans, J.J., Mattavelli, L., Padua, L., Reni, L., Bakkers, M., Boogerd, M., Campagnolo, M., Cazzaniga, M., Eurelings, M., Leandri, M., Lucchetta, M., Penas Prado, M., Russo, M., Piatti, M.L., Bidoli, P., Grant, R., Plasmati, R., Meijer, R.J., Dorsey, S.G., Galimberti, S., and Grisold, W.

Published
2013
Full Text
View/download PDF

7. Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin

Author

Alberti, P., Rossi, E., Cornblath, D. R., Merkies, I. S. J., Postma, T. J., Frigeni, B., Bruna, J., Velasco, R., Argyriou, A. A., Kalofonos, H. P., Psimaras, D., Ricard, D., Pace, A., Galiè, E., Briani, C., Dalla Torre, C., Faber, C. G., Lalisang, R. I., Boogerd, W., Brandsma, D., Koeppen, S., Hense, J., Storey, D., Kerrigan, S., Schenone, A., Fabbri, S., Valsecchi, M. G., Cavaletti, G., Cavaletti, G., Cornblath, D.R., Merkies, I.S.J., Postma, T.J., Valsecchi, M.G, Galimberti, S., Rossi, E., Cavaletti, G., Frigeni, B., Lanzani, F., Mattavelli, L., Piatti, ML., Alberti, P., Binda, D., Bidoli, P.., Cazzaniga, M., Cortinovis, D., Bruna, J., Velasco, R., Argyriou, AA., Kalofonos, HP., Psimaras, D., Ricard, D., Pace, A., Galiè, E., Briani, C., Lucchetta, M., Campagnolo, M., Dalla Torre, C., Merkies, ISJ., Faber, CG., Merkies, ISJ., Vanhoutte, EK., Bakkers, M., Brouwer, B., Lalisang, RI., Boogerd, W., Brandsma, D., Koeppen, S., Hense, J., Grant, R., Storey, D., Kerrigan, S., Schenone, A., Reni, L., Piras, B., Fabbri, S., Padua, L., Granata, G., Leandri, M., Ghignotti, I., Plasmati, R.., Pastorelli, F., Postma, TJ., Heimans, JJ., Eurelings, M., Meijer, RJ., Grisold, W., Lindeck Pozza, E., Mazzeo, A., Toscano, A., Tomasello, C., Altavilla, G., Penas Prado, M., Dominguez Gonzalez, C., Dorsey, SG., and Brell, JM.

Published
2014
Full Text
View/download PDF

8. Rasch-Transformed Total Neuropathy Score clinical version (RT-TNSc©) in patients with chemotherapy-induced peripheral neuropathy.

Author

Binda, Davide, Cavaletti, Guido, Cornblath, David R., Merkies, Ingemar S. J., Cavaletti, G., Cornblath, D.R., Merkies, I.S.J., Postma, T.J., Valsecchi, M.G., Galimberti, S., Rossi, E., Cavaletti, G, Frigeni, B, Lanzani, F, Mattavelli, L, Piatti, ML, Alberti, P, Binda, D, Bidoli, P, and Cazzaniga, M

Subjects
CANCER chemotherapy, EXPERIMENTAL design, RESEARCH methodology, PERIPHERAL neuropathy, HEALTH outcome assessment, RELIABILITY (Personality trait), STATISTICS, DATA analysis, RESEARCH methodology evaluation
Abstract

Composite scales such as the Total Neuropathy Score clinical version ( TNSc©) have been widely used to measure neurological impairment in a standardized manner but they have been criticized due to their ordinal setting having no fixed unit. This study aims to improve impairment assessment in patients with chemotherapy-induced peripheral neuropathy ( CIPN) by subjecting TNSc© records to Rasch analyses. In particular, we wanted to investigate the influence of factors affecting the use of the TNSc© in clinical practice. TNSc© has 7 domains (sensory, motor, autonomic, pin-prick, vibration, strength, and deep tendon reflexes [ DTR]) each being scored 0-4. Data obtained in 281 patients with stable CIPN were subjected to Rasch analyses to determine the fit to the model. The TNSc© did not meet Rasch model's expectations primarily because of misfit statistics in autonomic and DTR domains. Removing these two, acceptable model fit and uni-dimensionality were obtained. However, disordered thresholds (vibration and strength) and item bias (mainly cultural) were still seen, but these findings were kept to balance the assessment range of the Rasch-Transformed TNSc© ( RT-TNSc©). Acceptable reliability findings were also obtained. A 5-domains RT-TNSc© may be a more proper assessment tool in patients with CIPN. Future studies are needed to examine its responsive properties. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

9. A Case of Melas (A3243G) on Chronic Dichloroacetate Treatment.

Author

Curtò, N., Tremolizzo, L., Mattavelli, L., Piatti, M. L., Marzorati, L., Guerra, L., Grassi, M. G., and Ferrarese, C.

Subjects
LETTERS to the editor, CHRONIC diseases
Abstract

A letter to the editor is presented in response to the article "A Case of Melas (A3243G) on Chronic Dichloroacetate Treatment," by N. Curto, L. Tremolizzo, L. Mattavelli, M.L. Piatti, L. Marzorati, L. Guerra, M.G. Grassi and C. Ferrarese.

Published
2006
Full Text
View/download PDF

14. Chemotherapy-Induced Peripheral Neurotoxicity assessment: a critical revision of the currently available tools.

Author

Cavaletti G, Frigeni B, Lanzani F, Mattavelli L, Susani E, Alberti P, Cortinovis D, and Bidoli P

Abstract

Chemotherapy-Induced Peripheral Neurotoxicity (CIPN) is a frequent, potentially severe and dose-limiting side-effect of cancer treatment. Despite its clinical relevance that limits the use of several antineoplastic agents and even the future development of new anticancer drugs, several crucial aspects of CIPN remain unsolved, one of which is how to assess its occurrence and severity in the most effective and reliable way. CIPN severity is generally assessed using Common Toxicity Criteria (CTC) scales, although it is well known that significant inter-observer disagreement exists using these scales. Moreover, most CTC scores mix impairment, disability and quality of life measures, which could lead to misinterpretation of the results and unpredictable under- or overestimation of the effect. This uncertainty may lead to different interpretations of the results of the same clinical trials by clinicians and also by regulatory agencies. The use of other types of scale based on clinical and instrumental examinations, or the use of self-administered questionnaires for patients, has not yet really improved the accuracy of CIPN assessment, although some of these tools are promising and deserve to be further validated. As a result, there is a general recognition that CIPN has still not been properly assessed and that improvements should be made. In this review, the available data regarding the different tools used to assess CIPN will be revised and their features will be critically examined, with a special focus on their reliability and reproducibility across examiners and, when available, through direct comparison. [ABSTRACT FROM AUTHOR]

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results